Skip to Content

Copper chloride Disease Interactions

There are 4 disease interactions with copper chloride:

Moderate

Copper (applies to copper chloride) metabolic disorder

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Metabolic Disorder - Congenital

It is not recommended to administer copper to a patient with Wilson's Disease, a genetic disease of copper metabolism.

Moderate

Copper (applies to copper chloride) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Certain copper injectable formulations contain aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Patients with impaired kidney function who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration. Care is recommended when using this agent in patients with renal disease.

Moderate

Copper/manganese (applies to copper chloride) elimination

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease, Biliary Obstruction

The trace elements, copper and manganese, are excreted in the bile. Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.

References

  1. "Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group, Texarkana, TX.
  2. "Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc, Shirley, NY.
  3. "Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical, Abbott Park, IL.
Moderate

Trace metals (applies to copper chloride) malabsorption syndromes

Moderate Potential Hazard, Moderate plausibility.

The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements. GI absorption may be decreased in patients with malabsorption syndromes. Therefore, larger dosages may be required when these supplements are given orally. Parenteral administration may be appropriate.

References

  1. "Product Information. Chroma-Pak (chromic chloride)." Abbott Pharmaceutical, Abbott Park, IL.
  2. "Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical, Abbott Park, IL.
  3. "Product Information. Sele-Pak (selenious acid)." Fujisawa, Deerfield, IL.
  4. "Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc, Shirley, NY.
  5. "Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA, North Wales, PA.
  6. "Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group, Texarkana, TX.
View all 6 references

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.